Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2012 - 2023)
Gyre Therapeutics (GYRE) reported Preferred Stock Liabilities of $64.5 million for Q4 2023, up 93.72% year-over-year from $33.3 million in Q4 2022, and up 93.72% quarter-over-quarter from $33.3 million in Q2 2023.
Gyre Therapeutics (GYRE) Preferred Stock Liabilities (2012 - 2023) Analysis & Trends
Gyre Therapeutics (GYRE) has 5 years of Preferred Stock Liabilities data on file, last reported at $64.5 million in Q4 2023.
- Preferred Stock Liabilities for Q4 2023 came in at $64.5 million, up 93.72% year-over-year; the trailing twelve-month figure through Dec 2023 was $64.5 million (up 93.72% YoY), and the FY2023 annual result was $64.5 million, up 93.72% from the prior year.
- Preferred Stock Liabilities advanced to $64.5 million in Q4 2023 per GYRE's latest filing, from $33.3 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $64.5 million in Q4 2023 and troughed at $33.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 64.53 Mn |
| Jun 30, 2023 | 33.31 Mn |
| Mar 31, 2023 | 33.31 Mn |
| Dec 31, 2022 | 33.31 Mn |
| Dec 31, 2014 | 108.88 Mn |
| Dec 31, 2013 | 104.64 Mn |
| Dec 31, 2012 | 98.90 Mn |